ClinicalTrials.gg
RecruitingNCT03657017Updated Sep 4, 2018

PET/MR in Locally Advanced Nasopharyngeal Carcinoma

An interventional study of PET/MR in Nasopharyngeal Carcinoma and PET/MR, sponsored by Zhejiang Cancer Hospital. Recruiting at 1 site in China. Open to participants aged Up to 70 Years. Per ClinicalTrials.gov, last updated 2018-09-04.

Sponsored by Zhejiang Cancer Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2022, 4 years 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2018; still recruiting 8 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
Up to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Nasopharyngeal Carcinoma by Zhejiang Cancer Hospital — 6 open to participants now, 8 under way, none of them phase 3. Nasopharyngeal Carcinoma · Zhejiang Cancer Hospital.

Planned enrollment
6th of 19
150 · median 60
Started
2018
with 4 others
No phase
Only one
of the 23
Registered
13th of 23
by date

Among the 23 studies in Nasopharyngeal Carcinoma by Zhejiang Cancer Hospital, this one is the 6th largest by planned enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2018, is the only one with no phase, and was the 13th registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

6 of the 23 studies in Nasopharyngeal Carcinoma by Zhejiang Cancer Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: Up to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Nasopharyngeal Carcinoma by Zhejiang Cancer Hospital, or all of them as a file.
02

Study summary

PET/MR in Locally Advanced Nasopharyngeal Carcinoma

03

Conditions studied

  • Nasopharyngeal Carcinoma
  • PET/MR
04

Who can participate

Ages eligible
Up to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with newly confirmed non-keratinizing carcinoma.
  • Tumor staged T1-4N0-3M0 (according to the 8th AJCC staging system)
  • Performance status: >70
  • With normal liver function test (, AST \<1.5ULN)
  • Renal: >60ml/min
  • Without hematopathy,marrow: WBC >4*109/L, HGB>80G/L, and >100*109/L.
  • Written

Exclusion criteria

Exclusion Criteria:

  • Adenocarcinoma
  • Age >70
  • Prior (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin)
  • Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume)
  • Patient is pregnant or lactating
  • Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose >1.5×), or emotional disturbance.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Other
    PET/MR

    Patients are examined with PET/MR.

    Diagnostic Test: PET/MR

Interventions

  • Diagnostic testPET/MR

    Performed on a hybrid PET/MR scanner before treatment start (N = 150). Among those patients, 10 patients are examined with PET/MR in the completion of neoadjuvant chemotherapy and a follow-up scan three months after the completion of radiotherapy.

06

What researchers measure

Primary outcomes

  1. Multiparametric PET/MRI-based radiomics nomograms for locally advanced nasopharyngeal carcinoma

    Radiomics-based prognostic model by PET/MRI

    Time frame: From day 1 of chemotherapy to the date of the event, a minimum follow-up of 3 years.

Secondary outcomes

  1. Prediction model of the efficiency of treatment in locally advanced nasopharyngeal carcinoma

    Radiomics-based prediction model of the efficiency of treatment by PET/MRI

    Time frame: about 4 years (all of patients complete treatment)

07

Study locations

1 of 1 sites recruiting
  • Xiaozhong Chen
    Hangzhou, Zhejiang 310022, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2018 (actual). Primary completion is estimated for Jun 2022, 48 months after the start.

Of 49 interventional studies with no phase under Nasopharyngeal Carcinoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22. This study's planned 48 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2018
First posted
Sep 4, 2018
StartActual
Jun 1, 2018
Primary completionEst.
Jun 1, 2022
CompletionEst.
Dec 30, 2025
Last update
Sep 4, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03657017
Responsible party
Chen Xiaozhong (Clinical Professor, Zhejiang Cancer Hospital) — Principal investigator
First posted
Sep 4, 2018
Start date
Jun 1, 2018
Primary completion
Jun 1, 2022 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Sep 4, 2018

Study contacts

Caineng Cao, MD
Contact
caocaineng777@sina.com
0571-88128202

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion